Biomet Expands Its Spine Play

Biomet's recent acquisition of spine company InterporeCross expands its existing line of spine products but really is best seen as a follow-on to its recent buyout of its long-term alliance with German drug company Merck KGAA. Indeed, InterporeCross' major contribution in spine will come not in hardware, but in its strong orthobiologics program.

With Biomet Inc. 's acquisition of Interpore International Inc. (more familiarly known as Interpore Cross International), we see the latest in a series of moves by leading orthopedic suppliers into the heady spine market. [See Deal] Once largely shunned by the mainstream orthopedics companies, spine has become a hot market, driven both by its high growth rates, which are outpacing more traditional hip and knee lines, and its array of innovative technologies, which many in the spine market hope will drive further growth. Indeed, in that respect, Biomet's purchase price of nearly $300 million both represents a premium over Interpore's recent stock price and is right in range of other major spine deals in recent years, including Medtronic Inc. 's acquisition of Spinal Dynamics Inc. [See Deal], Synthes-Stratec 's purchase of Spine Solutions Inc. [See Deal] and Johnson & Johnson unit DePuy AcroMed Inc. 's acquisition of the Waldemar-Link GMBH & Co.'s spine business Link Spine Group Inc. [See Deal]

Of course, the Interpore Cross deal is far from Biomet's first foray into spine: the latter's product lines include more...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.